PeptiDream: J&J Latest Drug Major to Tie Up
On the surface, Peptidream's (4587 JP) deal with Johnson & Johnson's (JNJ US) Janssen unit looks no different from the deals they have cut with...
345 Views
Sosei & Kyowa Hakko Kirin: Positive News on GPCR Drugs
Kyowa Hakko Kirin's (4151 JP) announcement that “moga” – mogamulizumab (KW-0761) – has met its primary endpoint (PFS) in Phase III trials for...
297 Views
Astellas (4503) Implications of Ogeda Acquisition
At first glance, Astellas Pharma's decision to buy closely-held Belgian biotech firm Ogeda for ¥90bil (US$800mil) is essentially a licensing deal...
350 Views
Opdivo Singled Out in Government Rule Change
The suggestion of government orchestration against Ono’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the...
5.7k Views
Ono & Opdivo: Is the Backlash Orchestrated?
The announcement by the Japan Society of Medical Oncology (JSMO) urging patients to take caution over usage of immune checkpoint inhibitors, such...
258 Views